Profiel
Barrie Charles Finnin is the founder of Acrux Ltd.
which was founded in 1998.
He held the title of Non-Executive Director at Acrux Ltd.
Dr. Finnin's current job is Non-Executive Director at PolyActiva Pty Ltd.
Dr. Finnin's former job was External Evaluator at Therapeutic Goods Administration.
Actieve functies van Barrie Charles Finnin
Bedrijven | Functie | Begin |
---|---|---|
PolyActiva Pty Ltd.
PolyActiva Pty Ltd. BiotechnologyHealth Technology PolyActiva Pty Ltd. develops drug-polymer conjugate technology. Its platform technology is used to make plastic components for medical devices from drugs and manufacture process is novel and provides greater flexibility over the composition of the final material and better product outcomes compared with competitor technologies. The firm has built drug-polymer conjugates from a number of drug candidates with different chemical structures and linkage points, demonstrating the plasticity of the technology and developed a number of functional co-monomers and polymer segments, which modularises the production of the final conjugate. The company was founded in February 2010 and is headquartered in Melbourne, Australia. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Barrie Charles Finnin
Bedrijven | Functie | Einde |
---|---|---|
ACRUX LIMITED | Oprichter | - |
Therapeutic Goods Administration | Corporate Officer/Principal | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
ACRUX LIMITED | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
PolyActiva Pty Ltd.
PolyActiva Pty Ltd. BiotechnologyHealth Technology PolyActiva Pty Ltd. develops drug-polymer conjugate technology. Its platform technology is used to make plastic components for medical devices from drugs and manufacture process is novel and provides greater flexibility over the composition of the final material and better product outcomes compared with competitor technologies. The firm has built drug-polymer conjugates from a number of drug candidates with different chemical structures and linkage points, demonstrating the plasticity of the technology and developed a number of functional co-monomers and polymer segments, which modularises the production of the final conjugate. The company was founded in February 2010 and is headquartered in Melbourne, Australia. | Health Technology |
Therapeutic Goods Administration |